Passage Bio Reports Third Quarter 2020 Financial Results and Recent Business HighlightsGlobeNewsWire • 11/10/20
Passage Bio and Invitae Announce Collaboration to Facilitate Genetic Testing to Support Early Diagnosis and Greater Awareness of Clinical Trials for Patients with GM1GlobeNewsWire • 11/09/20
Passage Bio to Report Third Quarter 2020 Financial Results on November 10, 2020GlobeNewsWire • 11/04/20
Passage Bio's PBKR03 Receives Orphan Drug and Rare Pediatric Disease Designations from FDA for Treatment of Krabbe DiseaseGlobeNewsWire • 10/28/20
Passage Bio's PBGM01 Receives Orphan Drug Designation from EMA for Treatment of GM1 GangliosidosisGlobeNewsWire • 10/26/20